| Literature DB >> 27777973 |
Rintaro Saito1,2,3, Anaïs Rocanin-Arjo4, Young-Hyun You2,3, Manjula Darshi1,3, Benjamin Van Espen1,3, Satoshi Miyamoto2,3, Jessica Pham2,3, Minya Pu1,5, Simone Romoli4, Loki Natarajan1,5, Wenjun Ju6, Matthias Kretzler6, Robert Nelson7, Keiichiro Ono3, Dana Thomasova4, Shrikant R Mulay4, Trey Ideker3, Vivette D'Agati8, Ergin Beyret9, Juan Carlos Izpisua Belmonte9, Hans Joachim Anders4, Kumar Sharma1,2,3,10.
Abstract
To derive new insights in diabetic complications, we integrated publicly available human protein-protein interaction (PPI) networks with global metabolic networks using metabolomic data from patients with diabetic nephropathy. We focused on the participating proteins in the network that were computationally predicted to connect the urine metabolites. MDM2 had the highest significant number of PPI connections. As validation, significant downregulation of MDM2 gene expression was found in both glomerular and tubulointerstitial compartments of kidney biopsy tissue from 2 independent cohorts of patients with diabetic nephropathy. In diabetic mice, chemical inhibition of MDM2 with Nutlin-3a led to reduction in the number of podocytes, increased blood urea nitrogen, and increased mortality. Addition of Nutlin-3a decreased WT1+ cells in embryonic kidneys. Both podocyte- and tubule-specific MDM2-knockout mice exhibited severe glomerular and tubular dysfunction, respectively. Interestingly, the only 2 metabolites that were reduced in both podocyte and tubule-specific MDM2-knockout mice were 3-methylcrotonylglycine and uracil, both of which were also reduced in human diabetic kidney disease. Thus, our bioinformatics tool combined with multi-omics studies identified an important functional role for MDM2 in glomeruli and tubules of the diabetic nephropathic kidney and links MDM2 to a reduction in 2 key metabolite biomarkers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27777973 PMCID: PMC5070958 DOI: 10.1172/jci.insight.87877
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708